These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 35993470)

  • 21. Effects of aldose reductase inhibitor on microneurographically assessed peripheral sympathetic nerve activity in rats.
    Sato D; Kusunoki M; Shinzawa G; Feng Z; Nishina A; Nakamura T
    Auton Neurosci; 2015 Dec; 193():69-73. PubMed ID: 26272532
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Natural Compounds as Source of Aldose Reductase (AR) Inhibitors for the Treatment of Diabetic Complications: A Mini Review.
    Grewal AS; Thapa K; Kanojia N; Sharma N; Singh S
    Curr Drug Metab; 2020; 21(14):1091-1116. PubMed ID: 33069193
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of Aldose Reductase Inhibitors for the Treatment of Inflammatory Disorders and Cancer: Current Drug Design Strategies and Future Directions.
    Sonowal H; Ramana KV
    Curr Med Chem; 2021; 28(19):3683-3712. PubMed ID: 33109031
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aldose Reductase: a cause and a potential target for the treatment of diabetic complications.
    Thakur S; Gupta SK; Ali V; Singh P; Verma M
    Arch Pharm Res; 2021 Jul; 44(7):655-667. PubMed ID: 34279787
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aldose reductase inhibitors and nanodelivery of diabetic therapeutics.
    Prior AM; Thapa M; Hua DH
    Mini Rev Med Chem; 2012 Apr; 12(4):326-36. PubMed ID: 22303947
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial.
    Hotta N; Akanuma Y; Kawamori R; Matsuoka K; Oka Y; Shichiri M; Toyota T; Nakashima M; Yoshimura I; Sakamoto N; Shigeta Y
    Diabetes Care; 2006 Jul; 29(7):1538-44. PubMed ID: 16801576
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of aldose reductase inhibitors for diabetic gastroenteropathy with constipation.
    Nakamura T; Okano R; Uchiyama H; Seo Y; Okuda S
    Intern Med; 1997 Jul; 36(7):479-83. PubMed ID: 9240496
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acid Derivatives of Pyrazolo[1,5-a]pyrimidine as Aldose Reductase Differential Inhibitors.
    Balestri F; Quattrini L; Coviello V; Sartini S; Da Settimo F; Cappiello M; Moschini R; Del Corso A; Mura U; La Motta C
    Cell Chem Biol; 2018 Nov; 25(11):1414-1418.e3. PubMed ID: 30122369
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A selective aldose reductase inhibitor of a new structural class prevents or reverses early retinal abnormalities in experimental diabetic retinopathy.
    Sun W; Oates PJ; Coutcher JB; Gerhardinger C; Lorenzi M
    Diabetes; 2006 Oct; 55(10):2757-62. PubMed ID: 17003340
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epalrestat, an aldose reductase ihibitor, reduces the levels of Nepsilon-(carboxymethyl)lysine protein adducts and their precursors in erythrocytes from diabetic patients.
    Hamada Y; Nakamura J; Naruse K; Komori T; Kato K; Kasuya Y; Nagai R; Horiuchi S; Hotta N
    Diabetes Care; 2000 Oct; 23(10):1539-44. PubMed ID: 11023149
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protective effect of Tephrosia purpurea in diabetic cataract through aldose reductase inhibitory activity.
    Bhadada SV; Vyas VK; Goyal RK
    Biomed Pharmacother; 2016 Oct; 83():221-228. PubMed ID: 27372406
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An aldose reductase inhibitor reverses early diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense.
    Obrosova IG; Van Huysen C; Fathallah L; Cao XC; Greene DA; Stevens MJ
    FASEB J; 2002 Jan; 16(1):123-5. PubMed ID: 11709499
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ranirestat as a therapeutic aldose reductase inhibitor for diabetic complications.
    Giannoukakis N
    Expert Opin Investig Drugs; 2008 Apr; 17(4):575-81. PubMed ID: 18363521
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats.
    Cameron NE; Cotter MA; Basso M; Hohman TC
    Diabetologia; 1997 Mar; 40(3):271-81. PubMed ID: 9084964
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term effect of epalrestat on cardiac autonomic neuropathy in subjects with non-insulin dependent diabetes mellitus.
    Ikeda T; Iwata K; Tanaka Y
    Diabetes Res Clin Pract; 1999 Mar; 43(3):193-8. PubMed ID: 10369429
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aldose reductase inhibitors for the treatment of diabetic polyneuropathy.
    Chalk C; Benstead TJ; Moore F
    Cochrane Database Syst Rev; 2007 Oct; 2007(4):CD004572. PubMed ID: 17943821
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG.
    Iyer S; Sam FS; DiPrimio N; Preston G; Verheijen J; Murthy K; Parton Z; Tsang H; Lao J; Morava E; Perlstein EO
    Dis Model Mech; 2019 Nov; 12(11):. PubMed ID: 31636082
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic analysis of aldose reductase in diabetic complications.
    Chung SS; Chung SK
    Curr Med Chem; 2003 Aug; 10(15):1375-87. PubMed ID: 12871135
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The aldose reductase inhibitor epalrestat exerts nephritic protection on diabetic nephropathy in db/db mice through metabolic modulation.
    He J; Gao HX; Yang N; Zhu XD; Sun RB; Xie Y; Zeng CH; Zhang JW; Wang JK; Ding F; Aa JY; Wang GJ
    Acta Pharmacol Sin; 2019 Jan; 40(1):86-97. PubMed ID: 29930278
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aldose reductase structures: implications for mechanism and inhibition.
    El-Kabbani O; Ruiz F; Darmanin C; Chung RP
    Cell Mol Life Sci; 2004 Apr; 61(7-8):750-62. PubMed ID: 15095000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.